In a report issued on November 8, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG), with a price target of $127.00. The company’s shares closed last Tuesday at $121.18, close to its 52-week low of $112.00.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 8.2% and a 48.3% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Galapagos with a $141.29 average price target, representing a 14.7% upside. In a report issued on October 27, Raymond James also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Galapagos’ market cap is currently $8B and has a P/E ratio of 83.40. The company has a Price to Book ratio of 2.69.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Read More on GLPG:
